{"entity":{"id":"andres-ferreri","kind":"person","name":"Andrés J. M. Ferreri","aka":[],"tldr":"Led the IELSG trials that made MATRix induction and consolidation the standard for primary CNS lymphoma.","summary":"Andrés Ferreri led IELSG20, which established high-dose methotrexate plus cytarabine for primary CNS lymphoma, and IELSG32, which showed the MATRix regimen (adding rituximab and thiotepa) followed by autologous transplant or whole-brain radiotherapy produces durable remissions in most fit patients. He coordinates the International Extranodal Lymphoma Study Group and leads trials of novel agents in CNS and ocular lymphomas.","asOf":"2026-09-10","links":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ferreri%20AJM%5BAuthor%5D%20CNS%20lymphoma"}],"tags":["lymphoma","cns-lymphoma","ielsg"],"related":[],"cancers":["primary-cns-lymphoma"],"sections":[],"technologies":["cytotoxic-chemotherapy"],"targets":[],"drugs":[],"companies":["ielsg"],"institutions":["san-raffaele"],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"role":"Head of the Lymphoma Unit, IRCCS San Raffaele Scientific Institute, Milan","institutionId":"san-raffaele","specialisms":["Primary CNS lymphoma","Extranodal lymphomas","High-dose methotrexate regimens","Cooperative-group trials"],"profiles":[{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/?term=Ferreri%20AJM%5BAuthor%5D%20CNS%20lymphoma"}],"papers":[{"title":"Chemoimmunotherapy with methotrexate, cytarabine, thiotepa, and rituximab (MATRix regimen) in patients with primary CNS lymphoma: results of the first randomisation of the International Extranodal Lymphoma Study Group-32 (IELSG32) phase 2 trial","journal":"Lancet Haematology","year":2016,"doi":"10.1016/S2352-3026(16)00036-3"},{"title":"High-dose cytarabine plus high-dose methotrexate versus high-dose methotrexate alone in patients with primary CNS lymphoma (IELSG20)","journal":"Lancet","year":2009,"doi":"10.1016/S0140-6736(09)61416-1"}]},"route":"/people/andres-ferreri/","neighbours":{"cancer":[{"id":"primary-cns-lymphoma","kind":"cancer","name":"Primary CNS lymphoma","route":"/cancers/primary-cns-lymphoma/"}],"technology":[{"id":"cytotoxic-chemotherapy","kind":"technology","name":"Cytotoxic chemotherapy","route":"/technologies/cytotoxic-chemotherapy/"}],"company":[{"id":"ielsg","kind":"company","name":"International Extranodal Lymphoma Study Group","route":"/companies/ielsg/"}],"institution":[{"id":"san-raffaele","kind":"institution","name":"IRCCS Ospedale San Raffaele","route":"/institutions/san-raffaele/"}],"roadmap":[{"id":"lymphoma-roadmap","kind":"roadmap","name":"Lymphoma roadmap: from a jaw tumour in Uganda and the first human cancer virus to gene-expression subtypes, PET-adapted chemotherapy, CAR-T cells, bispecific antibodies and the genetics-directed trials now recruiting","route":"/roadmaps/lymphoma-roadmap/"}]}}